[Intra-arterial infusion chemotherapy with epirubicin for advanced breast cancer]. 1991

Y Takatsuka, and T Kawahara, and E Yayoi, and J Okamura, and K Miyauchi, and T Mori
Dept. of Surgery, Osaka National Hospital.

Thirty-two patients with locally advanced or disseminated breast cancer were treated with preoperative intra-arterial infusion chemotherapy with epirubicin (30 mg/m2, day 1, 4, 7). The results were as follows: 1) the response rate (CR + PR) was as high as 71.9% (23/32) in the primary lesions. Marked degenerative changes were, also, histologically observed in 22 cases (68.8%). 2) As for side effects, mild grade of leukopenia and hair loss were frequently encountered in 75.0% and 62.5%, respectively. Gastrointestinal disorders, however, was extremely rare (6.3%). 3) Follow-up time was not long enough, but considerable survival advantages were suggested. The author confirmed that intra-arterial infusion chemotherapy with epirubicin was an efficacious modality for the treatment of advanced breast cancer.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015251 Epirubicin An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. 4'-Epiadriamycin,4'-Epidoxorubicin,4'-Epi-Adriamycin,4'-Epi-DXR,4'-Epi-Doxorubicin,EPI-cell,Ellence,Epilem,Epirubicin Hydrochloride,Farmorubicin,Farmorubicina,Farmorubicine,IMI-28,NSC-256942,Pharmorubicin,4' Epi Adriamycin,4' Epi DXR,4' Epi Doxorubicin,4' Epiadriamycin,4' Epidoxorubicin,EPI cell,EPIcell,Hydrochloride, Epirubicin,IMI 28,IMI28,NSC 256942,NSC256942

Related Publications

Y Takatsuka, and T Kawahara, and E Yayoi, and J Okamura, and K Miyauchi, and T Mori
August 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Takatsuka, and T Kawahara, and E Yayoi, and J Okamura, and K Miyauchi, and T Mori
November 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Takatsuka, and T Kawahara, and E Yayoi, and J Okamura, and K Miyauchi, and T Mori
September 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Takatsuka, and T Kawahara, and E Yayoi, and J Okamura, and K Miyauchi, and T Mori
February 2002, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Takatsuka, and T Kawahara, and E Yayoi, and J Okamura, and K Miyauchi, and T Mori
October 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Takatsuka, and T Kawahara, and E Yayoi, and J Okamura, and K Miyauchi, and T Mori
January 2000, Oncology reports,
Y Takatsuka, and T Kawahara, and E Yayoi, and J Okamura, and K Miyauchi, and T Mori
August 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Takatsuka, and T Kawahara, and E Yayoi, and J Okamura, and K Miyauchi, and T Mori
April 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Takatsuka, and T Kawahara, and E Yayoi, and J Okamura, and K Miyauchi, and T Mori
January 2003, Anticancer research,
Y Takatsuka, and T Kawahara, and E Yayoi, and J Okamura, and K Miyauchi, and T Mori
November 2009, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!